Glimison-M 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination of these agents provides complementary mechanisms of action, resulting in improved glycemic control in patients inadequately controlled by diet and exercise alone. Glimison-M 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to assess therapeutic response and adjust dosage accordingly. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, primarily attributed to metformin, while hypoglycemia risk is associated with glimepiride use. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Patient adherence and periodic monitoring of renal function and glycemic parameters are essential to optimize treatment outcomes and minimize potential risks.